Osteoporosis Flashcards

1
Q

Osteoporosis

A
  • most common metabolic bone disease
  • low bone mass but normally mineralized bone
  • Microarchitectural disruption –> skeletal fragility
  • Major risk factor for fracture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology of osteoporosis

A
  • 8mill women, 2mill men (more women bc of menopause)
  • 43mill w/ bone mass that puts them at risk (called osteopoenia), 10mill with osteoporosis
  • 30% women >50yo have low bone mass
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

osteopenia

A

precursor for osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

At what age does bone mass typically decrease

A

30-40yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what causes osteoporosis

A
  • bones naturally get thinner as you age because existing bone cells are reabsorbed faster than new bone is made
  • the thicker your bones at age 30, the longer it takes to develop osteopenia or osteoporosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

types and percentages of osteoporotic fractures

A
  • 50% vertebral fractures (700k per yr) –> mostly asymptomatic, height loss, kypohosis, back pain
  • 25% hip fractures (300k per yr) –> a lot of older pts, risk for DVT, PE; HIGH MORTALITY!!
  • 25% colles’ fractures (250k per yr) –> fall onto outstretched hand (younger pt), fracture of distal radius
  • increased fracture risk in spine, hip, wrist, humerus, and pelvis
  • osteoporotic fractures = fragility fractures (falls from standing height or less)
  • fractures of hip or spine are associated with 10-20% increase in mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

nonmodifiable risk factors

A
  • h/o fracture
  • family h/o fracture
  • female
  • old
  • Caucasian/Asian
  • Dementia (less likely to remember to take osteoporotic meds including vitamins)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

modifiable risk factors

A
  • cigarettes (may inhibit osteoblast activity, interfere with calcium absorption)
  • low body weight (high is better)
  • low estrogen
  • low calcium intake
  • chronic steroids
  • alcoholism
  • poor eyesight
  • recurrent falls
  • low physical activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Protective factors

A
  • high BMI
  • black race
  • estrogen or diuretic therapy (diuretics bc decrease calcium excretion by kidneys)
  • exercise (start as a kid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pathogenesis of osteoporosis

A
  • slow loss of cortical and trabecular bone as you age
  • rapid loss of trabecular bone postmenopause
  • any process that increases rate of bone remodeling results in net bone loss over time
  • Genetic component (40-80%) –> genes involving vitD synth, E receptors, bone forming proteins
  • Environmental –> calcium intake, muscle strength and physical activity, chronic dz, meds, smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

coupling

A

resorption followed by formation (or mineralization)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

bone remodeling

A
  • resorption followed by formation
  • continually removes older bone and replaces it with new bone –> maintains healthy skeleton
  • repairs microdamage in skeleton
  • supply Ca from skeleton to body
  • mass of the skeleton remains constant once peak bone mass is reached
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

osteoporosis in trabecular bone

A
  • osteoclasts penetrate trabeculae leaving no template for new bone formation
  • age related loss of horizontal connections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

osteoporosis in cortical bone

A
  • increased activation/remodeling leads to more porous bones

- decreased bone strength

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how does estrogen deficiency cause bone loss

A
  • activates new bone remodeling sites
  • exaggerates imbalance between formation and resorption
  • increased osteoclast recruitment and activity
  • increased osteoblast apoptosis
  • AFFECTS TRABECULAR BONE FIRST
  • in men, T is important because it is converted to E to build bones
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how does calcium deficiency cause bone loss

A
  • increased rate of bone remodeling to maintain adequate serum calcium
  • PTH is secreted when there is low calcium –> increases Ca resorption from bone, decreases renal Ca excretion, increases renal production of 1,25-dihydroxyvitamin D (hormonal form of vitD that optimizes Ca and phos absorption and inhibits PTH synth)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

vitD deficiency

A
  • most common nutritional deficiency worldwide
  • most underdiagnosed medical condition
  • sever, prolonged deficiency can lead to hypocalcemia, rickets, osteomalacia, osteoporosis
  • high risk: sun avoidance/sunscreen, poor nutrition, malabsorption, old, liver or renal dz, living in northern lats
  • vitD promotes Ca absorption in GI and is needed by osteoblasts and osteoclasts for bone growth and remodeling
  • may be a link between vitD deficiency and DM, cancer, autoimmune dz, CT dz, autism, childhood obesity, preg complications, depression, schizo
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

vit D metabolism

A
  • activation of vitD to calcitriol = increase in serum calcium and phosphate concentrations
  • fat soluble that is naturally present in foods, added to others, available as dietary supplement
  • produced endogenously via UV rays
  • vitD from sunlight, food, and supplements is biologically inert and must undergo two hydroxylations in body for activation (first in liver converted to 25 hydroxyvitD aka calcidiol, second in kidney converted to 1,25 dihydroxyvitD aka calcitriol)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

sources of vitamin D

A
  • body makes it when exposed to UV
  • cheese, margarine, butter, fortified milke, healthy cereals, fatty fish, shitake mushrooms, cod liver oil
  • vitamin D fortified milk - 400iu per quart
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

rickets

A
  • vitamin D deficiency
  • decreased mineralization around epiphyses and bowing of lower extremities
  • growth retardation
  • only in GROWING children - before fusion of epiphyses
  • Pregnant women and children must have sufficient vitD and Ca intake
  • most common cause is nutritional deficiency of vitD - even in hot climates ppl avoid sun, cover skin, dark skinned ppl require more sun to synth vitD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

osteomalacia

A
  • vitD deficiency

- incomplete mineralization of underlying mature bone matrix (osteoid) following growth plate closure in adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

osteomalacia vs. rickets

A
  • diff manifestations of same underlying pathologic process

- can occur concurrently when growth plates are open, osteomlacia cna continue after growth plates fuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

laboratory testing for vitD

A
  • serum OH-vitD, total: major circulating form of vitD
  • represents endogenous production, diet, and supplementation (D2 + D3)
  • D2 = exogenous, diet, supplementation
  • D3 = endogenous from UV, supplementation
  • normal range = 30-100ng/mL
  • vitD defic = <20ng/mL
  • vitD insuff = <30ng/mL
  • 25-OHD3 - measure of endogenous production and supplementation
  • 25-OHD2 - measure of exogenous sources - diet, supplementation
24
Q

treatment for low vitD

A

-cholecalciferol (D3) 1000-2000IU x8 weeks

OR

  • Ergocalciferol (D2) 50,000IU QW or QOW x6-8 weeks
  • after above tx, follow w/ maintenance dose D3 400-1000IU qd
25
Q

25-OHD3

A

measure of endogenous production and supplementation

26
Q

25-OHD2

A

measure of exogenous sources - diet, supplementation

27
Q

1-25 dihydroxy vitamin D

A
  • tests biologically active form of vitD
  • should not be used to assess overall vitD status
  • useful for establishing inherited or acquired disorders of vitD metabolism, and other disorders i.e. sarcoidosis, lymphoma, TB, CKD
28
Q

parathyroid hormone

A

hormone released by parathyroid glands that regulates calcium and phosphate homeostasis

29
Q

primary vs. secondary hyperparathyroidism

A
  • primary = parathyroid adenoma causes inappropriate release of PTH - results in hypercalcemia and potential osteopenia/osteoporosis
  • secondary = commonly due to vitamin D deficiency! can also be due to severe calcium deficiency, chornic kidney disease
  • if you see abnormal Ca on a lab, check PTH and vitD before referring to endo
30
Q

clinical presentation of osteoporosis

A
  • usually asymptomatic until fractures occur
  • loss of height, kyphosis, back pain w/ vertebral fractures (2/3 asymptomatic)
  • falls from standing that cause hip or wrist fractures
31
Q

radiographic features of osteoporosis

A

-spinal osteoporosis shows wedging of vertebrae anteriorly w/ vertebral collapse, vertebral end-plate irregularity, and general demineralization

32
Q

What to look for on physical exam for osteoporosis

A
  • hyperthyroidism
  • hypogonadism
  • renal dz
  • cancer (especially multiple myeloma)
  • diabetes
  • GI or liver dz
33
Q

multiple myeloma - osteoporosis

A
  • can be a cause of low Ca
  • CRAB –> C = calcium (elevated), R = renal failure, A = anemia, B = bone lesions
  • bone pain is common
34
Q

diabetes - osteoporosis

A
  • early onset is associated w/ reduced bone density
  • type 1 shows evidence of low bone mass following adolescence
  • type 2 pts do not have low bone mass (increased BMI), may be protected from osteoporosis
  • bone turnover is suppressed in pts with poor glycemic control, returns to normal with normalization of glycemia
35
Q

lab testing - osteoporosis

A
  • chem panel: electrolytes, BUN, creatinine, Ca, Mg, Phos, Alk phos, albumin
  • TSH
  • Serum T (males)
  • CBC
  • PTH and serum 25-OHvitD
  • albumin is marker of nutritional status, necessary to calculate corrected calcium
  • Alk phos made in the liver and bone - high levels can mean Paget’s dz, osteomalacia
36
Q

Bone Densitometry

A
  • GOLD STANDARD IS DXA or DEXA
  • x-ray used to estimate bone mineral density
  • normal bone density = >-1.0
  • osteopenia = -1.0 to -2.5
  • osteoporosis =
37
Q

Types of bone densitometry

A
  • SPA –> peripheral (radius, calcaneus)
  • DPA –> axial (spine, hip)
  • DXA or DEXA –> GOLD STANDARD, spine, hip, low radiation
  • Quantitative computed tomography –> expensive, high radiation
  • ultrasonography –> heel
38
Q

DXA or DEXA

A
  • best clinical method for diagnosis, monitoring osteoporosis
  • T-score value used for diagnosis (compared to a standard database) (compares pts BMD with that of healthy 30yo of your sex)
  • Z-score value used in reference to age, sex, ethnicity (determines age, sex, and ethnicity norms)
39
Q

WHO criteria for DXA diagnosis of osteoporosis

A
  • normal = BMD w/in 1 SD of young normal adult, T-score -1.0 or higher
  • low bone mass, or osteopenia = BMD between 1 and 2.5 SD lower than that of young normal adult, T-score between -1.0 and -2.5
  • osteoporosis = BMD more than 2.5 SD lower than that of young normal adult, T-score -2.5 or lower
40
Q

screening for osteoporosis

A
  • all women aged >/= 65 years
  • post-menopausal women >/= 60 if risk factors present
  • hip with DXA scan recommended
  • Tx of asymptomatic women will reduce risk of fractures
  • all men aged >/= 70
  • men < 70 if risk factors present
  • risk factors = low body weight, prior fracture, high risk medication use, dz or condition associated with bone loss
  • Screen every 2-3 yrs
41
Q

Who to Tx

A
  • PMP women and men (>50) w/ hx of hip or vertebral fracture
  • any pt with osteoporosis (T score = -2.5)
  • any pt with osteopenia (T score -1.0 to -2.5) AND an estimated 10-yr risk of hip or osteoporosis related fracture
42
Q

nonpharmacologic therapy

A
  • adequate Ca and vitD intake (diet and supplementation)
  • exercise - integral part of treatment
  • weight bearing, muscle strengthening activities
  • smoking cessation and limit ETOH
  • avoid glucocorticoids and other drugs that increase bone loss
  • gluten-free diet for celiac disease
  • address risk factors (protective padding for hips)
43
Q

Pharmacologic therapy

A
  • bisphosphonates
  • selective estrogen receptor modulators (SERMs)
  • Denosumab
  • Estrogen (estrogen and progestin)
  • Parathyroid hormone
  • calcitonin
  • Ca and vitD for everyone!
44
Q

Bisphosphonates

A
  • alendronate (fosamax) 70mg/wk
  • Risedronate (actonel) 35mg/wk or 150mg/month
  • Ibandronate (boniva) 150mg/month
  • Soledronic acid (Reclast) 5mg IV q12 months
45
Q

Bisphosphonates MOA

A
  • 1st line for prevention and treatment
  • inhibits osteoclast activity, reducing bone resorption and turnover
  • increase bone mass, decrease fracture risk
46
Q

Bisphosphonates use and side effects

A
  • may cause erosive esophagitis (take on empty stomach, remain upright 30 mins
  • duration of tx = 5-7 yrs, consider drug holiday
  • prefer oral bisphosphonates as initial tx b/c efficacy, favorable cost, availability of long-term safety data
  • alendronate or risedronate = initial choice
  • all have uncommon but severe rx of osteonecrosis of jaw (more likely with IV form and dental surgery)
  • this drug is retained in skeleton for more than 10 yrs
  • as soon as you get a dexo where it doesn’t change or goes down, that’s your cue to stop bisphosphonates
  • Alendronate prevents bone loss at hip
47
Q

Selective estrogen receptor modulators (SERMs)

A
  • Raloxifene (Evista) 60mg/day
  • prevention and tx
  • selectively binds E receptors, inhibiting bone resorption and turnover
  • also lowers serum LDL, decreases risk vertebral fractures, decreases risk breast cancer
  • Risks = DVT, PE, contraindicated in women with hx of CVA, CHD
  • MC side effect - hot flashes
  • Raloxifene reproduces beneficial effects of E on the skeletal systems w/out negative effects of E on breast and endometrium
48
Q

Denosumab (prolia)

A
  • RANK-ligand inhibitor
  • reduces bone turnover and resorption by inhibiting osteoclast activity
  • 60mg SC q6mos
  • indicated for PMP women w/ high risk of fracture or failure of other tx
  • reduces incidence of vertebral, nonvertebral and hip fractures
  • ADE = back pain, hypercholesterolemia, hypocalcemia
49
Q

Estrogen/Progestin

A
  • various preparations and doses
  • reduce bone turnover, prevent bone loss, increase bone mineral density, reduce fracture risk
  • increased risk of breast cancer, stroke, thromboembolism, and CAD
  • may be indicated in symptomatic menopausal women with osteoporosis
  • REDUCES HIP FRACTURE
50
Q

PTH

A
  • Teripartide (Forteo) 20 or 40 mcg/d SQ for no longer than 24 mos
  • stimulates bone formation
  • approved for treatment in high-risk pts
  • ONLY TX THAT PROMOTES NEW BONE FORMATION
  • acts on osteoblast cells, stimulating them to overactivity
  • BBW of osteosarcoma in high doses for long duration of tx
51
Q

Calcitonin

A
  • Miacalcin 200IU/day intranasally
  • tx, not prevention
  • suppress osteoclast
  • best for pts w/ pain from osteoporotic fractures for up to 4 wks, improves bone pain
  • risk of tachyphylaxis
  • not as effective as other options
  • recent cancer warning
52
Q

calcium/vitD supplements

A

-Ca 1000-1200 mg/day in divided doses with food intake
-VitD 800-1000IU/day
Best preps are calcium carbonate + vitD bid-tid with food
-body cant absorb more than 500mg of Ca at a time so divided doses are best

53
Q

Calcium supplements

A
  • calcium carbonate = tums (cheaper, best absorbed with food)
  • Calcium citrate = Citracal (more expensive, can take on full or empty stomach, absorbed better)
  • both are recommended for all adults >50
  • average daily Ca intake in adults >50 = 600-700 mg/day
  • Ca intake more than 1200-1500mg per day can increase risk of developing kidney stones, CV dz, and stroke
54
Q

Recommended dietary allowances for Calcium

A
  • Age Male Female Pregnant Lactating
  • 0–6 months* 200 mg 200 mg
  • 7–12 months* 260 mg 260 mg
  • 1–3 years 700 mg 700 mg
  • 4–8 years 1,000 mg 1,000 mg
  • 9–13 years 1,300 mg 1,300 mg
  • 14–18 years 1,300 mg 1,300 mg 1,300 mg 1,300 mg
  • 19–50 years 1,000 mg 1,000 mg 1,000 mg 1,000 mg
  • 51–70 years 1,000 mg 1,200 mg
  • 71+ years 1,200 mg 1,200 mg
55
Q

Dietary sources of calcium

A

-leafy greens, cheese, milk, yogurt, etc.

56
Q

Follow up for osteoporosis

A
  • measure bone mineral density again 12-24 mos after beginning tx
  • 4% change in spine or 6% change in hip considered significant
  • if BMD declines at 2 yrs, discuss compliance or consider secondary causes of osteoporosis
  • another way to monitor = bone markers (used in endo, not FP) –> N-telopeptide cross-linked type I collagen, osteocalcin